Aclipse Therapeutics

About:

Aclipse Therapeutics focuses on developing differentiated drugs to address diseases with unmet medical needs.

Website: https://www.aclipsetherapeutics.com/

Twitter/X: AclipseOne

Top Investors: U.S. Department of Defense, Medical Research Council, Intellectual Digital Global (iDG), FightMND, Intellectual Digital Corp. (iDC)

Description:

Aclipse Therapeutics is a biopharmaceutical company that focuses on developing differentiated drugs to address diseases with unmet medical needs. Its strategy is reducing clinical development risk by combining a new and druggable understanding of disease pathways with a novel drug molecule that inhibits these pathways, allowing us to build upon existing nonclinical and clinical data while creating a significant patent barrier-to-entry.

Total Funding Amount:

$5.57M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Radnor, Pennsylvania, United States

Founded Date:

2017-01-01

Contact Email:

info(AT)aclipsetherapeutics.com

Founders:

Ning Shan, Raymond K. Houck

Number of Employees:

1-10

Last Funding Date:

2022-04-20

IPO Status:

Private

Industries:

© 2025 bioDAO.ai